24,327 reports of this reaction
9.1% of all EVOLOCUMAB reports
#2 most reported adverse reaction
DRUG DOSE OMISSION BY DEVICE is the #2 most commonly reported adverse reaction for EVOLOCUMAB, manufactured by Amgen USA Inc.. There are 24,327 FDA adverse event reports linking EVOLOCUMAB to DRUG DOSE OMISSION BY DEVICE. This represents approximately 9.1% of all 266,603 adverse event reports for this drug.
Patients taking EVOLOCUMAB who experience drug dose omission by device should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION BY DEVICE is moderately reported among EVOLOCUMAB users, representing a notable but not dominant share of adverse events.
In addition to drug dose omission by device, the following adverse reactions have been reported for EVOLOCUMAB:
The following drugs have also been linked to drug dose omission by device in FDA adverse event reports:
DRUG DOSE OMISSION BY DEVICE has been reported as an adverse event in 24,327 FDA reports for EVOLOCUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION BY DEVICE accounts for approximately 9.1% of all adverse event reports for EVOLOCUMAB, making it one of the most commonly reported side effect.
If you experience drug dose omission by device while taking EVOLOCUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.